Sight Sciences CEO Badawi sells $108k in shares

Sight Sciences won a $34.0M patent-infringement award (including $5.5M lost profits and $28.5M in royalties) and reported Q4 2025 EPS of -$0.08 vs. consensus -$0.15 with revenue of $20.4M vs. $20.17M (≈7% revenue growth). President & CEO Paul Badawi sold 29,244 shares on April 1 at $3.63–$3.85 for $108,202 to cover RSU taxes and now directly holds 6,151,156 shares (including 606,173 unvested RSUs); the stock trades at $3.52, down 9.3% over the past week. William Blair reiterated an Outperform rating, and the combination of the legal win and modest earnings beat supports a constructive near-term view on the equity.

Analysis

The court ruling materially improves Sight Sciences’ negotiating leverage with larger OEMs: it converts an execution risk into a licensable asset rather than a one-off operational beat. That leverage shortens the time-to-revenue if management pursues settlement/royalty discussions aggressively, because large competitors typically prefer controlled payouts to protracted injunction risk, creating a plausible 6–24 month path to recurring cash inflows.

Insider selling tied to RSU tax events should be treated as neutral for conviction but highlights concentrated insider exposure and ongoing dilution dynamics from equity compensation; monitor future vesting cliffs for potential transient supply pressure. Equally important is the IP durability pathway — PTAB/appeal outcomes and settlement mechanics are the primary value drivers, so legal timelines will dominate volatility more than product uptake in the next 12–18 months.

From a tactical fund perspective, the risk profile is asymmetric: limited operational scale today but binary upside from IP monetization versus meaningful downside from adverse appeals or execution slips. Short-term catalysts to trade around are quarterly cadence and legal procedural milestones; medium-term re-rating depends on either a monetized royalty stream or demonstrable durable margin expansion from licensing proceeds.

Key Decisions for Investors

• Small-long equity exposure in SGHT (1–2% portfolio) with a 12-month protective put to cap downside at ~15% and a target take-profit at +60–100% if a licensing announcement or settlement occurs within 12–18 months; this preserves upside while limiting capital at risk.
• 12–18 month call-spread (buy lower strike / sell higher strike) on SGHT to create a defined-cost, leveraged bet on monetization events — target a 2.5–4x upside on premium paid if settlement/royalty recognition happens, with total premium ≤1% portfolio.
• Pair trade: long SGHT / short ALC sized to dollar-neutrality to isolate idiosyncratic IP upside vs incumbent defensive dynamics; horizon 6–24 months. Stop-loss: 20% on either leg; thesis profits if SGHT captures licensing value while ALC de-rates on litigation overhang.
• If long SGHT equity post-catalyst, convert to income by selling near-term covered calls after a 30–50% rally to realize gains and reduce tail risk from protracted appeals; reassess after each legal procedural milestone.